Novartis at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Novartis brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on what happens to AAV in the body after dosing. Topics include long-read sequencing of rAAV integration in primary human liver cells and the systemic immune response in patients given a single injection under the retina.
| Organization | ESGCT 2026 Attendance |
|---|---|
Novartis Basel, Switzerland | |
Global pharmaceutical company whose marketed products include the gene therapy Zolgensma and the CAR-T therapy Kymriah. | Talk Tue Oct 27 5:30pm–7:30pm Long-read TES to study rAAV integration: from benchmarking in clonal systems to insights in primary human hepatocytes Vectors and delivery (AAV, lentiviral, LNP) Poster Wed Oct 28 1:30pm–3:30pm Systemic immune responses in patients administered a single subretinal injection of an AAV2-based gene therapy |
Instantly find 20 buyers from Novartis
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction